Scalper1 News
Gilead Sciences (GILD) picked up another provider for its hepatitis C drugs Friday in the ongoing battle for market share in that disease. Giant health insurer Aetna announced on its website that “Harvoni and Sovaldi will now be preferred therapies for Aetna Commercial customers” after the two companies negotiated an unspecified discount on the drugs’ prices. Officially, Sovaldi, which is usually taken with at least one other drug, costs $84,000 Scalper1 News
Scalper1 News